ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
55 announcements with these filters
Thyrocare delivered strong Q1 FY27 results with 24% YoY consolidated revenue growth and 34% YoY PAT growth, driven by pathology network expansion and high-value specialty test launches.
Thyrocare Technologies Ltd reported revenue from operations of ₹240 Cr (+24.4% YoY) and net profit of ₹51.3 Cr (+33.9% YoY) for Q1 FY27.
Thyrocare Technologies scheduled a board meeting on July 23, 2026. The board will consider unaudited financial results for the quarter ended June 30, 2026.
Thyrocare Technologies announced amendments to its Memorandum of Association. These changes were approved by members during the 26th Annual General Meeting.
Thyrocare appointed M/s. Price Waterhouse Chartered Accountants LLP as Statutory Auditors. This follows the term completion of M/s. M S K A & Associates LLP.
Thyrocare Technologies held its 26th AGM on June 30, 2026. All proposed ordinary and special resolutions were duly passed.
Thyrocare Technologies approved a ₹5.50 Crore cash equity infusion into its subsidiary, Think Health Diagnostics. The investment supports working capital and business operations through multiple tranches.
Docon Technologies reported a Rs.30 Crore partial redemption of NCDs linked to its share encumbrance in Thyrocare Technologies. The number of pledged shares remains unchanged.
Thyrocare Technologies convened its 26th Annual General Meeting for June 30, 2026. Agenda items include dividend declaration, director appointments, and MoA amendments for shareholder approval.
Thyrocare Technologies fixed June 23, 2026, as the record date for its ₹7.00 final dividend. Payment remains subject to shareholder approval at the upcoming June AGM.
Thyrocare Technologies Limited submitted its Business Responsibility and Sustainability Report for FY 2025-26. The report details the company's environmental, social, and governance performance and initiatives.
Thyrocare Technologies submitted its FY 2025-26 Annual Report and 26th AGM notice. The meeting is scheduled for June 30, 2026.
Thyrocare reports strong Q4 FY26 results with 20% consolidated revenue growth and 128% PAT surge, driven by volume growth and core pathology expansion.
Thyrocare Technologies announced a leadership overhaul including the appointment of Price Waterhouse as statutory auditors and two new directors. CEO Rahul Guha was re-appointed for five years.
Thyrocare Technologies recommended a final dividend of Rs. 7.00 per share for FY2025-26. Total annual dividend reached Rs. 9.33 per share following shareholder approval.
Thyrocare Technologies reported FY26 consolidated revenue of ₹829.04 Crore, up 21% YoY. Net profit surged 81% to ₹162.85 Crore, driven by pathology segment growth.
Thyrocare reports strong performance for Q4FY26 and FY26 with significant YoY growth in PAT and EBITDA driven by network expansion and operational efficiencies.
Thyrocare reports robust growth for Q4FY26 and FY26, driven by franchise expansion and new specialty launches like Genomics and Allergy testing.
Thyrocare Technologies Ltd reported revenue from operations of ₹223.9 Cr (+19.6% YoY) and net profit of ₹48.7 Cr (+125.5% YoY) for Q4 FY26.
Thyrocare Technologies reported FY26 consolidated revenue of ₹829.04 Crore and PAT of ₹162.85 Crore. The Board recommended a final dividend of ₹7.00 per share and approved the appointment of Price Waterhouse LLP as Statutory Auditors. The company also announced a ₹5.50 Crore investment in its wholly-owned subsidiary, Think Health Diagnostics.
Thyrocare Technologies Ltd has cancelled its Earnings Conference Call originally scheduled for May 07, 2026, at 5:30 P.M. (IST) due to unforeseen circumstances. The call was intended to discuss the company's audited financial results for the quarter and year ended March 31, 2026. A revised schedule will be announced later.
Thyrocare Technologies Limited has scheduled a Board Meeting for May 7, 2026. The board will consider audited standalone and consolidated financial results for the year ended March 31, 2026, and recommend a final dividend. The trading window remains closed until May 9, 2026.
Thyrocare Technologies Ltd will hold a Board meeting on May 07, 2026, to approve audited financial results for FY26 and recommend a final dividend. The company's trading window closed on April 01, 2026, and will reopen 48 hours after the results declaration.
Thyrocare Technologies Ltd reported net profit of ₹28.1 Cr (+48.7% YoY) for Q3 FY26.
Thyrocare Technologies submitted its Regulation 74(5) compliance certificate for the quarter ended March 31, 2026. The Registrar and Share Transfer Agent confirmed that the entire shareholding is in dematerialised form and no rematerialisation requests were received during the period.